News
VIVE
--
0.00%
--
Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan
ENGLEWOOD, CO / ACCESSWIRE / April 1, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No.
ACCESSWIRE · 04/01 13:28
Viveve Announces Expansion Of IP Portfolio With Patent Issuance In Taiwan
Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No. 1720358 for
Benzinga · 04/01 12:29
Viveve Medical: Lincoln Park Capital to Sell Up to 3.5M Shrs
Viveve Medical: Lincoln Park Capital to Sell Up to 3.5M Shrs
Dow Jones · 03/31 22:43
BRIEF-Viveve Medical Files Prospectus Related To Resale Of Up To 3.5 Million Shares By Lincoln Park Capital Fund
reuters.com · 03/31 21:17
BRIEF-Viveve Medical Inc Says On March 31 Co, Lincoln Park Capital Fund Entered Into First Amendment To Purchase Agreement
reuters.com · 03/31 21:14
DJ Viveve Medical, Inc. CEO Scott Durbin on Q4 2020 Results -- Earnings Call Transcript >VIVE
Dow Jones · 03/19 03:23
Viveve Reports Full Year 2020 Financial Results and Provides Corporate Update
Company continuing to advance its U. pivotal PURSUIT trial in stress urinary incontinence Conference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / March 18, 2021 / Viveve Medical, Inc.
ACCESSWIRE · 03/18 21:02
Viveve Medical, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 18, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 18, 2021 at 5:00 PM Eastern Time.
ACCESSWIRE · 03/18 20:15
Viveve Medical EPS beats by $0.67, beats on revenue
Viveve Medical (VIVE): FY GAAP EPS of -$16.56 beats by $0.67.Revenue of $5.48M (-16.6% Y/Y) beats by $0.1M.Cash and cash equivalents were $6.5 million as of December 31, 2020, compared
Seekingalpha · 03/18 20:06
Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations
Biotech stocks snapped back from their weekly losses and ended higher for the week ended March 12, with the broader market recovery partly aiding the reversal.
Benzinga · 03/14 12:14
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4)
Benzinga · 03/05 13:15
Viveve to Participate in the H.C. Wainwright Global Life Sciences Virtual Conference
ENGLEWOOD, CO / ACCESSWIRE / March 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the virtual H.C. Wainwright Gl...
ACCESSWIRE · 03/02 13:29
The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 19)
Benzinga · 02/19 12:25
Viveve Medical Expects 4Q Rev of About $1.9M
Viveve Medical Expects 4Q Rev of About $1.9M
Dow Jones · 02/18 22:28
Viveve estimates Y/Y growth in Q4 revenue
Viveve Medical (VIVE) traded down 1% after hours on estimating Q4 revenue at $1.9M vs. $1.5M in year ago quarter; global sales of disposable treatment tips increased 48% Y/Y.As of Dec. 31, 2020, the
Seekingalpha · 02/18 21:56
BRIEF-Viveve Medical Says Co Has Capital Resources To Support Operations Through Year-End 2022
reuters.com · 02/18 21:52
Viveve Announces Preliminary Topline Financial Results for Fourth Quarter 2020
ACCESSWIRE · 02/18 21:02
Viveve Recognized for Leadership in Appointing Women to Board of Directors
Colorado Women on Boards Coalition names Viveve as top Colorado public companyENGLEWOOD, CO / ACCESSWIRE / February 9, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Colo...
ACCESSWIRE · 02/09 13:28
BRIEF-Viveve Medical Announces Expansion Of IP Portfolio With Issuance Of S. Korean Patent
reuters.com · 02/02 13:41
Viveve Announces South Korean Patent Titled 'Vaginal Remodeling Device and Method'
ENGLEWOOD, CO / ACCESSWIRE / February 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Korean Intellectual Property Office
Benzinga · 02/02 13:30
Webull provides a variety of real-time VIVE stock news. You can receive the latest news about Viveve Medical through multiple platforms. This information may help you make smarter investment decisions.
About VIVE
Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company's, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician's office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.